Skip to main content
. 2022 Oct 29;11(21):6421. doi: 10.3390/jcm11216421

Figure 1.

Figure 1

ITGB2 expression was downregulated in NSCLC, and its low levels were associated with a poor prognosis in the public databases. (A,B) Genetic changes in ITGB2, analyzed by cBioPortal, based on the TCGA lung cancer dataset (A) and OncoSG and CPTAC datasets (B). (C,D) Expression of ITGB2 in LUAD tissue and adjacent normal tissue (C) and LUAD of different tumor stages (D) in the TCGA database (UCLCAN). (E,F) Expression of ITGB2 in LUSC tissue and adjacent normal tissue (E) and LUSC of different tumor stages (F) in the TCGA database (UCLCAN). (G–I) Expression of ITGB2 in NSCLC tissue and adjacent normal tissue (G), in LUAD tissue and adjacent normal tissue (H), and in LUSC tissue and adjacent normal tissue (I) according to the GEO cohort. (J) Kaplan−Meier survival curves for the overall survival (OS) according to ITGB2’s expression levels in NSCLC. **** P < 0.0001.